ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Tadalafil

Also written as “tadalafil”, “Tadalafil 20 mg” and “Cialis Tab. 5mg”.

Its studies are mostly in Erectile Dysfunction · Prostatic Hyperplasia · Hypertension, Pulmonary · Pulmonary Arterial Hypertension · Carcinoma, Non-Small-Cell Lung, led by 8 companies.

Drug pageTadalafil: every studyMany companies study it; this page follows only the 59 they lead. All 193 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 31, 200659 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only490 open or runningphase 4since May 31, 2006Dec 16, 2002none ahead
Chong Kun Dang Pharmaceuticalits history only30 open or runningphase 3since Sep 2, 2015Sep 15, 2014none ahead
Pfizerits history only20 open or runningphase 2since Sep 12, 2005Sep 12, 2005none ahead
Futura Medical Developmentsits history only10 open or runningphase 3since Jul 26, 2021Jul 26, 2021none ahead
Hanmi Pharmaceuticalits history only10 open or runningphase 1since Sep 4, 2014Sep 4, 2014none ahead
lidia-larran-agaits history only10 open or runningphase 3since May 6, 2020May 6, 2020none ahead
Sanofi10 open or runningphase 3since Jan 17, 2025Jan 17, 2025none ahead
Seattle Gummyits history only11 open or runningphase 1since Feb 17, 2021Feb 17, 2021none ahead

Also a collaborator on its studies: Bristol-Myers Squibb, Gilead Sciences, Nippon Shinyaku and ICOS.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 17, 2025First study: phase 3 study in Erectile DysfunctionFirst studyNCT06805513 · 2,212 enrolled · United States

TargetBeta

PDE5A →read by rule
“Phosphodiesterase 5A inhibitor”ChEMBL 37, by rule

Other programs on PDE5A

ProgramCompanyFurthest phaseStudies
sildenafilruleViatrisphase 474

Studies

The one study Sanofi leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06805513Erectile Dysfunction · United States3CompletedMar 2, 20262,212

How it is read

Names in the registry

  • “tadalafil”, 45 entries
  • “Tadalafil”, 25 entries
  • “Tadalafil 20 mg”, 2 entries
  • “Cialis Tab. 5mg”, 2 entries
  • “Tadalafil 5 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.